The HS-1 associated protein X-1 (HAX-1) is a ubiquitously expressed protein that protects cardiomyocytes from programmed cell death. HAX-1 is mainly located in cardiac mitochondria and sarcoplasmic reticulum. Recently, it has been recognized that HAX-1 serves as a binding partner of phospholamban, which plays a fundamental role in controlling basal contractility and constitutes a key downstream effector of the β-adrenergic signaling cascade. However, the functional significance of HAX-1 in the heart remains unclear. Our previous studies have shown that overexpression of HAX-1 in vitro or in vivo by adenoviruses and transgenesis reduced cardiac myocyte contractility and calcium transients under basal condition without significant alterations of isoproterenol response. Conversely, in vitro downregulation of HAX-1 enhanced calcium kinetics and mechanics under basal conditions.
Background
The HS-1 associated protein X-1 (HAX-1) is a ubiquitously expressed protein that protects cardiomyocytes from programmed cell death. HAX-1 is mainly located in cardiac mitochondria and sarcoplasmic reticulum. Recently, it has been recognized that HAX-1 serves as a binding partner of phospholamban, which plays a fundamental role in controlling basal contractility and constitutes a key downstream effector of the β-adrenergic signaling cascade. However, the functional significance of HAX-1 in the heart remains unclear. Our previous studies have shown that overexpression of HAX-1 in vitro or in vivo by adenoviruses and transgenesis reduced cardiac myocyte contractility and calcium transients under basal condition without significant alterations of isoproterenol response. Conversely, in vitro downregulation of HAX-1 enhanced calcium kinetics and mechanics under basal conditions.
Methods and results
To further investigate the role of the endogenous HAX-1 in the cardiac contractile function, HAX-1 heterozygous deficient mice with 36% of HAX-1 expression in the heart were characterized, since the homozygous mice are lethal at 5-12 weeks afterbirth. Interestingly, in vivo echocardiography showed that decreased HAX-1 expression was associated with significantly enhanced cardiac performance, including fractional shortening and ejection frac-tion, when compared to age-matched wild types. Ex-vivo Langendorff perfusion suggested markedly increased rates of contraction and relaxation, compared to wild types (Figure 1) . Furthermore, at the cardiomyocyte levels, we also found similar cardiac phenotype with elevated fractional shortening, rates of contraction and relaxation as well as calcium kinetics under basal conditions. The functional improvement in the heterozygous HAX-1 deficient mouse hearts does not plays a role in the expressions of major SR calcium handling proteins, including: SERCA2a, calsequestrin and phospholamban. However, the affinity of SERCA2 for calcium was significantly increased without alteration of maximal velocity of this calcium pump. The enhanced cardiac contractility is not related to any significant cardiac remodeling and histology changes at the age of 10-12 weeks.
Conclusion
These results indicate that decreased HAX-1 expression in the heart is associated with increased cardiac contractility and calcium handling, suggesting that HAX-1 may be a novel regulator in cardiac contractile performance.
